Moderators: Ramez Eskander, MD & Fiona Simpkins, MD

• Phase 2, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor (ER) Positive Recurrent or Persistent Endometrial Cancer – Speaker: P. Konstantinopoulos
• EGFL6 is an Important Growth Factor Involved in Endometrial Cancer Tumorigenesis – Speaker: A. Garrett
• A Novel Combo of Niraparib and Anlotinib in Platinum-Resistant Ovarian Cancer, the Final Efficacy and Safety Report of ANNIE Study, a Phase II, Multi-Center Trial – Speaker: J. Liu
• Distillation – Speaker: S. Westin
• Efficacy and Safety of Serplulimab (an anti-PD-1 antibody) Combined with Albumin-Bound Paclitaxel in Patients with Advanced Cervical Cancer who Have Progressive Disease or Intolerable Toxicity After First-Line Standard Chemotherapy – Speaker: J. An
• Efficacy and Safety of Cadonilimab, an Anti-PD-1/CTLA4 Bi-Specific Antibody, in Previously Treated Recurrent or Metastatic (R/M) Cervical Cancer: A Multicenter, Open-Label, Single-Arm, Phase II Trial – Speaker: X. Wu
• Distillation – Speaker: N. Colombo
• Updated Results from the Phase 1 Expansion Study of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian Cancer – Speaker: D. Richardson
• Clinical Outcomes of Ovarian Cancer Patients Treated with the Novel Engineered Cytokine Nemvaleukin Alfa in Combination with the PD-1 Inhibitor Pembrolizumab: Recent Data from ARTISTRY-1 – Speaker: I. Winer
• Distillation – Speaker: K. Fuh

This session was recorded live at the 2022 AM on Women’s Cancer in March 2022.